Published in Br J Cancer on September 13, 2004
Do benign thyroid nodules have malignant potential? An evidence-based review. World J Surg (2008) 1.85
Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer? J Surg Res (2007) 1.75
The clinical features of papillary thyroid cancer in Hashimoto's thyroiditis patients from an area with a high prevalence of Hashimoto's disease. BMC Cancer (2012) 1.07
Should patients with symptomatic Hashimoto's thyroiditis pursue surgery? J Surg Res (2011) 0.87
Is thyroidectomy in patients with Hashimoto thyroiditis more risky? J Surg Res (2012) 0.82
MicroRNA-mediated networks underlie immune response regulation in papillary thyroid carcinoma. Sci Rep (2014) 0.82
Interleukin-10 but not interleukin-18 may be associated with the immune response against well-differentiated thyroid cancer. Clinics (Sao Paulo) (2011) 0.81
Report of a case of papillary thyroid carcinoma in association with Hashimoto's thyroiditis. Niger Med J (2016) 0.75
Auto-antibodies in Hashimoto's disease (lymphadenoid goitre). Lancet (1956) 5.32
Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res (1996) 3.89
The enemy within: keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol (2002) 3.47
Molecular mimicry by herpes simplex virus-type 1: autoimmune disease after viral infection. Science (1998) 3.15
Chronic autoimmune thyroiditis. N Engl J Med (1996) 2.71
Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science (1997) 2.56
Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A (2001) 2.38
Evidence of limited variability of antigen receptors on intrathyroidal T cells in autoimmune thyroid disease. N Engl J Med (1991) 2.21
Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. Laryngoscope (1997) 2.15
Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours. Virchows Arch (1996) 1.59
Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet (2001) 1.54
FasL expression on epithelial cells: the Bottazzo-Feldman hypothesis revisited. Immunol Today (1997) 1.46
Galectins in cell growth and apoptosis. Cell Mol Life Sci (2003) 1.41
Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas. Int J Surg Pathol (2002) 1.33
Genome-wide appraisal of thyroid cancer progression. Am J Pathol (2002) 1.28
Autoimmune thyroid disease: new models of cell death in autoimmunity. Nat Rev Immunol (2002) 1.27
Prevalence of thyroid autoantibodies in children and adolescents from Belarus exposed to the Chernobyl radioactive fallout. Lancet (1998) 1.20
Malignant transformation of thyroid follicular cells by galectin-3. Cancer Lett (2003) 1.13
The role of cell cycle regulatory protein, cyclin D1, in the progression of thyroid cancer. Mod Pathol (2000) 1.11
Thyroid diseases among atomic bomb survivors in Nagasaki. JAMA (1994) 1.02
Struma lymphomatosa (Hashimoto's thyroiditis). Observations on repeated biopsies in sixteen patients. N Engl J Med (1961) 0.97
A long term clinical, immunological, and histological follow-up study of patients with goitrous chronic lymphocytic thyroiditis. J Clin Endocrinol Metab (1985) 0.94
Met protein and hepatocyte growth factor (HGF) in papillary carcinoma of the thyroid: evidence for a pathogenetic role in tumourigenesis. J Pathol (2001) 0.92
Hashimoto's thyroiditis: an organ-specific autoimmune disease--pathogenesis and recent developments. Lab Invest (1999) 0.87
Karyotypic characterization of papillary thyroid carcinomas. Cancer (2001) 0.87
Analysis of apoptosis in relation to tissue destruction associated with Hashimoto's autoimmune thyroiditis. J Pathol (1997) 0.86
Loss of heterozygosity mutations of tumor suppressor genes in cytologically atypical areas in chronic lymphocytic thyroiditis. Endocr Pathol (2002) 0.84
Differential loss of heterozygosity at 7q31.2 in follicular and papillary thyroid tumors. Oncogene (1998) 0.84
Pathomorphology of thyroid gland lesions associated with radiation exposure: the Chernobyl experience and review of the literature. Adv Anat Pathol (1999) 0.81
A thyroid tumor-specific antigen formed by the fusion of two self proteins. J Immunol (2003) 0.80
Pathogenesis of thyroid autoimmunity: the Bottazzo-Feldmann hypothesis. Immunol Today (1998) 0.78
Cytogenetics of thyroid nodules in Hashimoto thyroiditis. Cancer Genet Cytogenet (2000) 0.78
Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ (2007) 8.08
Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J Cell Biol (1998) 5.32
The origin and function of tumor-associated macrophages. Immunol Today (1992) 5.12
Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc Natl Acad Sci U S A (1999) 3.49
Monoclonal antibodies specific for endothelial cells of mouse blood vessels. Their application in the identification of adult and embryonic endothelium. Eur J Cell Biol (1994) 3.31
Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. Diabetes (2000) 3.01
Control of target cell survival in thyroid autoimmunity by T helper cytokines via regulation of apoptotic proteins. Nat Immunol (2000) 2.98
Constitutive activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 transgenic mice. EMBO J (2000) 2.41
ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol (2006) 2.34
Retrieved endogenous biotin: a novel marker and a potential pitfall in diagnostic immunohistochemistry. Histopathology (1997) 2.31
Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab (2001) 2.13
Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest (2001) 2.10
Differential localization of VE- and N-cadherins in human endothelial cells: VE-cadherin competes with N-cadherin for junctional localization. J Cell Biol (1998) 2.08
Thyroid disease classification. Lancet (2000) 2.00
Expression of the neuroendocrine phenotype in carcinomas of the breast. Semin Diagn Pathol (2000) 1.94
Polymorphonuclear leukocyte adhesion triggers the disorganization of endothelial cell-to-cell adherens junctions. J Cell Biol (1996) 1.90
Diagnostic accuracy of conventional versus sonography-guided fine-needle aspiration biopsy of thyroid nodules. Thyroid (1998) 1.75
Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene (2011) 1.75
Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet (2001) 1.68
IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol (1998) 1.63
Electrocardiographic signs of chronic cor pulmonale: A negative prognostic finding in chronic obstructive pulmonary disease. Circulation (1999) 1.63
Characteristics, associations and outcome of absent pulmonary valve syndrome in the fetus. Ultrasound Obstet Gynecol (2004) 1.54
Esophageal metastasis from clear cell carcinoma of the kidney. Am J Gastroenterol (1997) 1.54
Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet (2001) 1.54
A modified cell block technique for fine needle aspiration cytology. Acta Cytol (1995) 1.51
Apocrine carcinoma of the skin. A clinicopathologic, immunocytochemical, and ultrastructural study. Cancer (1993) 1.48
Prospective randomized evaluation of preoperative endoscopic vital staining using CH-40 for lymph node dissection in gastric cancer. Ann Surg Oncol (1999) 1.47
Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans. J Endocrinol Invest (2000) 1.44
Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons. J Cell Biol (1995) 1.43
Gastric carcinoids and their precursor lesions. A histologic and immunohistochemical study of 23 cases. Cancer (1991) 1.42
Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women. Mod Pathol (2001) 1.41
Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. J Clin Endocrinol Metab (2004) 1.40
Acromegaly due to ectopic secretion of GHRH by bronchial carcinoid in a patient with empty sella. J Endocrinol Invest (2003) 1.40
Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. J Clin Endocrinol Metab (2001) 1.37
β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells. Oncogene (2011) 1.34
Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab (2001) 1.32
Secondary and tertiary hyperparathyroidism: causes of recurrent disease after 446 parathyroidectomies. Ann Surg (2001) 1.27
Clinical significance of neuroendocrine carcinoma of the breast. Ann Oncol (2001) 1.16
Epithelioid lymphangioleiomyomatosis-like tumour of the uterus in a patient without tuberous sclerosis: a lesion mimicking epithelioid leiomyosarcoma. Histopathology (1998) 1.15
Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer (2005) 1.14
Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alpha 2b. Hepatology (1993) 1.14
A new monoclonal antibody (5D3-F7) which recognizes human monocyte-chemotactic protein-1 but not related chemokines. Development of a sandwich ELISA and in situ detection of producing cells. J Immunol Methods (1994) 1.12
Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer (1999) 1.10
Mixed medullary-follicular thyroid carcinoma. Molecular evidence for a dual origin of tumor components. Am J Pathol (1999) 1.10
Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. Hum Pathol (2001) 1.09
[A uterine pecoma: a case report]. G Chir (1999) 1.08
Integrin expression in cutaneous malignant melanoma: association of the alpha 3/beta 1 heterodimer with tumor progression. Int J Cancer (1993) 1.07
Stearoyl-CoA desaturase-1 is a key factor for lung cancer-initiating cells. Cell Death Dis (2013) 1.07
Erythropoietin/erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma. Histopathology (2007) 1.06
Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clin Exp Immunol (2007) 1.05
Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.04
Cytological classification of thyroid nodules. Proposal of the SIAPEC-IAP Italian Consensus Working Group. Pathologica (2010) 1.04
Ghrelin: more than a natural GH secretagogue and/or an orexigenic factor. Clin Endocrinol (Oxf) (2005) 1.04
Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br J Cancer (1999) 1.04
Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS (2001) 1.02
Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. Cancer Res (2000) 1.01
Erythropoietin as an angiogenic factor in gastric carcinoma. Histopathology (2003) 1.00
Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Int J Cancer (2000) 1.00
Trend in thyroid carcinoma size, age at diagnosis, and histology in a retrospective study of 500 cases diagnosed over 20 years. Thyroid (2006) 0.99
Binding of antibodies against human prealbumin to intestinal and bronchial carcinoids and to pancreatic endocrine tumours. Virchows Arch B Cell Pathol Incl Mol Pathol (1984) 0.99
Papillary carcinoma of the thyroid: low expression of NCAM (CD56) is associated with downregulation of VEGF-D production by tumour cells. J Pathol (2007) 0.99
HIPK2 is involved in cell proliferation and its suppression promotes growth arrest independently of DNA damage. Cell Prolif (2009) 0.99
Expression of VE (vascular endothelial)-cadherin and other endothelial-specific markers in haemangiomas. J Pathol (1995) 0.98
Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. Ann Oncol (2009) 0.97
Pathological and molecular features of adrenocortical carcinoma: an update. J Clin Pathol (2008) 0.97
HIPK2 phosphorylates ΔNp63α and promotes its degradation in response to DNA damage. Oncogene (2011) 0.97
A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone. Hepatology (2001) 0.97
Mapping a dominant form of multinodular goiter to chromosome Xp22. Am J Hum Genet (2000) 0.96
Grading the neuroendocrine tumors of the lung: an evidence-based proposal. Endocr Relat Cancer (2013) 0.96
Neovascularisation, expression of fibroblast growth factor-2, and mast cells with tryptase activity increase simultaneously with pathological progression in human malignant melanoma. Eur J Cancer (2003) 0.95
Evidence of overadditive interaction between fenoterol and ipratropium bromide in the counteraction of cholinomimetic-induced tracheobronchial contractions. Arzneimittelforschung (1981) 0.95
Association of HLA class I and class II antigen expression and mortality in uveal melanoma. Invest Ophthalmol Vis Sci (2001) 0.95
Thrombospondin-1 inhibits Kaposi's sarcoma (KS) cell and HIV-1 Tat-induced angiogenesis and is poorly expressed in KS lesions. J Pathol (1999) 0.94
Cortistatin, but not somatostatin, binds to growth hormone secretagogue (GHS) receptors of human pituitary gland. J Endocrinol Invest (2001) 0.93
Binding of 125I-labeled ghrelin to membranes from human hypothalamus and pituitary gland. J Endocrinol Invest (2001) 0.93
Common arterial trunk in the fetus: characteristics, associations, and outcome in a multicentre series of 23 cases. Heart (2003) 0.93
Preoperative T staging of gastric carcinoma obtained by MDCT vessel probe reconstructions and correlations with histological findings. Eur Radiol (2009) 0.93
Pulmonary giant cell carcinoma: pathological entity or morphological phenotype? Histopathology (1998) 0.92
Interleukins 1 beta and 6 induce functional alteration of rat colonic motility: an in vitro study. Eur J Clin Invest (2003) 0.92
Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas. J Endocrinol Invest (2004) 0.92
Isolation and partial characterization of the plasma membrane of purified bovine neutrophils. Eur J Biochem (1980) 0.92
Do mast cells help to induce angiogenesis in B-cell non-Hodgkin's lymphomas? Br J Cancer (1998) 0.92
Specific haplotypes of the RET proto-oncogene are over-represented in patients with sporadic papillary thyroid carcinoma. J Med Genet (2002) 0.91
Immunohistochemical analysis of benign and malignant papillary lesions of the breast. Am J Surg Pathol (1983) 0.91
Expression of Met protein in thyroid tumours. J Pathol (1996) 0.91
Biological effects of Escherichia coli lipopolysaccharide (LPS) in vivo. I. Selection in the mouse thymus of killer and helper cells. Immunology (1976) 0.91
Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study. Cancer Invest (2013) 0.91
Expression and production of tenascin in benign and malignant lesions of melanocyte lineage. Int J Cancer (1990) 0.91
Surgical experience with carotid stenosis in young HIV-1 positive patients under antiretroviral therapy: an emerging problem? Eur J Vasc Endovasc Surg (2005) 0.90
Cytologic features of poorly differentiated 'insular' carcinoma of the thyroid, as revealed by fine-needle aspiration biopsy. Am J Clin Pathol (1990) 0.90
Characterization of MEC 14.7, a new monoclonal antibody recognizing mouse CD34: a useful reage for identifying and characterizing blood vessels and hematopoietic precursors. Eur J Cell Biol (1997) 0.90
Action of insulin receptor substrate-3 (IRS-3) and IRS-4 to stimulate translocation of GLUT4 in rat adipose cells. Mol Endocrinol (1999) 0.90
Large needle aspiration biopsy and galectin-3 determination in selected thyroid nodules with indeterminate FNA-cytology. Br J Cancer (2006) 0.90
Short term respiratory effects of acute exposure to chlorine due to a swimming pool accident. Occup Environ Med (2001) 0.90
Monoclonal antibodies to glutathione S-transferase pi-immunohistochemical analysis of human tissues and cancers. Int J Cancer (1991) 0.89